In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best cheap stocks to buy for 2025. The U.S. consumer prices report released this week revealed a ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lill ...

After catching up with Pfizer’s Chairman and CEO, CFO, Chief Scientific Officer and Chief Strategy and Innovation Officer at the firm’s healthcare conference, JPMorgan analyst ...

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional ...

In the latest trading session, Pfizer (PFE) closed at $26.64, marking a +1.29% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.88% for the day. Meanwhile, the ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.